HEMOPHILIA TREATMENT MARKET ANALYSIS

Global hemophilia treatment market is estimated to be valued at US$ 15,197.8 million in 2023 and is expected to exhibit a CAGR of 6.33% during the forecast period (2023-2030). Adoption of inorganic strategies such as partnerships, collaborations, and others by key market players is expected to drive the global hemophilia treatment market growth over the forecast period. For instance, in December 2019, Bayer, pharmaceutical and biotechnology company, announced it had entered into a three-year collaboration with the Children's Hospital of Philadelphia (CHOP). This partnership will combine CHOP's expertise in hemophilia and coagulation and Bayer's research capabilities, and will lead  to discovery and development of first-in-class oral non-replacement therapy (NRT) for the treatment of hemophilia A and B.

Government authorities are taking initiatives to introduce new products for better management of hemophilia treatment. Thus, increasing  number of product approvals is likely drive the growth of market. For instance,  in November 2022, U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor IX deficiency). Factor IX protein increases blood levels of Factor IX and thus limits the bleeding. The National Hemophilia foundation (NHF) is actively working to upspring the awareness regarding symptoms, diagnosis, and treatment of hemophilia A.

Global Hemophilia Treatment Market- Driver

Government authorities are taking initiatives to introduce new products for better management of hemophilia treatment. Thus, increasing number of product approvals is likely to drive the growth of market.

Global Hemophilia Treatment Market- Driver

Increasing government initiatives and awareness towards hemophilia  

Government authorities are taking initiatives to introduce new products for better management of hemophilia treatment. Thus, increasing  number of product approvals is likely to drive the growth of market. For instance,  in November 2022, U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor IX deficiency). Factor IX protein increases blood levels of Factor IX and thus limits the bleeding. The National Hemophilia foundation (NHF) is actively working to upspring the awareness regarding symptoms, diagnosis, and treatment of hemophilia A.

Global Hemophilia Treatment Market- Trends

Figure 1. Global Hemophilia Treatment Market Share (%), By Product type, 2023

Global Hemophilia Treatment Market- Market Trends